Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Burning Rock Dx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Burning Rock Collaborates with IMPACT Therapeutics to Provide Testing Services in Developing IMP9064 in Both US And China","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Dingxin Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Impact Therapeutics Announces Completion of Series D1 Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Granted Orphan Drug Designation to IMP4297+TMZ for SCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMPACT Therapeutics Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Eikon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by IMPACT Therapeutics, Inc

    Menu

    IMPACT Therapeutics, Inc

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              IMPACT Therapeutics, Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors

              Details:

              Under the collaboration, Eikon received an exclusive license from Impact to co-develop, register, manufacture, and commercialize IMP1734 and other PARP1 selective inhibitors globally, excluding Greater China.

              Lead Product(s): IMP1734

              Therapeutic Area: Oncology Product Name: IMP1734

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Eikon Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration June 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IMPACT Therapeutics, Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IMPACT Therapeutics Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint

              Details:

              IMP4927 (senaparib) is a PARP inhibitor, being investigated as monotherapy maintenance treatment following first-line platinum-based chemotherapy in patients with FIGO stage III/IV ovarian cancer who have achieved complete response or partial response.

              Lead Product(s): Senaparib

              Therapeutic Area: Oncology Product Name: IMP4927

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Shanghai Junshi Biosciences

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 12, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IMPACT Therapeutics, Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              FDA Granted Orphan Drug Designation to IMP4297+TMZ for SCLC

              Details:

              The preliminary clinical results for a phase I b/II study investigating the PARP inhibitor IMP4297 having Senaparib in combination with temozolomide (TMZ) for the treatment of advanced solid tumors.

              Lead Product(s): Senaparib,Temozolomide

              Therapeutic Area: Oncology Product Name: IMP4297

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 19, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IMPACT Therapeutics, Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Impact Therapeutics Announces Completion of Series D1 Financing

              Details:

              Proceeds will be used to accelerate the development of its synthetic lethality programs, including IMP4297, which are showing best-in-class potential. The company already has three synthetic lethality compounds in the clinical stage.

              Lead Product(s): Senaparib

              Therapeutic Area: Oncology Product Name: IMP4297

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Dingxin Capital

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Series D Financing March 14, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IMPACT Therapeutics, Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Burning Rock Collaborates with IMPACT Therapeutics to Provide Testing Services in Developing IMP9064 in Both US And China

              Details:

              Under the collaboration, Burning Rock will provide the testing services in connection with IMPACT Therapeutics’ development of its ATR inhibitor IMP9064, with worldwide intellectual property rights.

              Lead Product(s): IMP9064,Senaparib

              Therapeutic Area: Oncology Product Name: IMP9064

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Burning Rock Dx

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration November 04, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY